Patients with a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, a new study found.
A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for the ...
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...
District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...
Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...
A Cleveland Clinic-led research collaboration between Timothy Chan, MD, PhD, Chair of Cleveland Clinic's Global Center for ...
The Food and Drug Administration in the US has just approved Cobenfy, which one researcher referred to as a "game changer" ...
As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime ...
Among patients with Crohn's disease, anti-TNF therapy failed to achieve remission at 3 years, and high drug concentrations early in treatment were linked to greater probability of sustained remission.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback